Liraglutide Therapy and Weight Control in Adolescents with Severe Obesity: A Real-World Experience
Year: 2026
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: Adolescent obesity remains a major clinical challenge, with limited effective treatment options beyond lifestyle modification. Liraglutide, a glucagon-like peptide-1 receptor agonist approved for adolescents aged ≥ 12 years, has shown promising results in clinical trials; however, real-world data remain scarce. This study aimed to evaluate the real-world effectiveness and tolerability of liraglutide in adolescents with severe obesity, including weight, body composition, and metabolic outcomes. METHODS: This retrospective longitudinal cohort study included adolescents with obesity aged 12-19 years who received liraglutide therapy. Anthropometric, biochemical, body composition, and adverse event data were assessed monthly. RESULTS: A total of 29 adolescents with obesity (13 males) were included (mean age: 15.7 ± 2.0 years; mean body mass index (BMI): 38.6 ± 6.0 kg/m2; body mass index standard deviation score (BMI-SDS): 3.38 ± 0.57). - BMI-SDS decreased progressively, with an estimated reduction of 0.46 from baseline to month 6; the decline was numerically faster in the first 3 months than in months 3-6, without reaching statistical significance (P = .11). Lean mass percentage increased and total fat percentage decreased after 3 months (both P < .05). Total cholesterol, fasting insulin, and homeostasis model assessment of insulin resistance decreased significantly, while other metabolic parameters remained unchanged. Gastrointestinal adverse events were common; 3 patients discontinued due to intolerance and 1 due to gallstones. CONCLUSION: In this real-world cohort, liraglutide treatment was associated with early and clinically meaningful reductions in BMI-SDS and improvements in insulin sensitivity in adolescents with severe obesity. The therapy was generally well tolerated, though gastrointestinal side effects and financial barriers limited treatment persistence. Longer-term prospective studies are needed to assess durability and cardiometabolic outcomes.
Source: Turkish Archives of Pediatrics
Authors: Hasan Karakaş(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing), Gürkan Tarçın(Conceptualization, Formal analysis, Methodology, Writing – review & editing), Hande Turan(Conceptualization, Investigation, Methodology, Supervision), Didem Güneş Kaya(Conceptualization, Investigation), İlayda Altun(Conceptualization, Investigation), Mert Uçar(Conceptualization, Investigation), Gökçe Velioğlu Haşlak(Conceptualization, Investigation), Elvan Bayramoğlu(Conceptualization, Methodology, Supervision), Olcay Evliyaoğlu(Conceptualization, Formal analysis, Methodology, Supervision, Writing – original draft, Writing – review & editing)
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7235609486
